Dupilumab inhibits the IL-4/IL-13 signaling pathway to reduce itching and itching in atopic dermatitis, which may reduce the release of CCL20 from keratinocytes and also reduce Th17 cell infiltration [38]. This evidence concerns the gene IL13 and atopic eczema.